Is There An ‘October Surprise’ Coming For Drug Pricing?

 
• By Ben Comer

US Congressional Democrats made Halloween the new deadline for President Biden’s Build Back Better Act, to be passed through the reconciliation process. Savings generated from prescription drug price cuts represent a key pot of money to offset the legislation’s other spending initiatives.

jack-o-lantern
• Source: Alamy

Negotiations are ongoing between various factions of the democratic party, in both the House and the Senate, with the goal of passing the Build Back Better Act by a self-imposed deadline of 31 October. House legislation placed an initial price tag of $3.5tn on the package, but the Senate is likely to cut that figure down to around $2tn, said Ryan Urgo, managing director, health policy, Avalere Health, during a 15 October webcast.

Drug pricing legislation is expected to be a part of the final bill. The question of the moment is whether...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.